[{"address1": "4 Kingsbury Avenue", "city": "Watertown", "state": "MA", "zip": "02472", "country": "United States", "phone": "617 607 0800", "fax": "617 607 0530", "website": "https://www.enanta.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.", "fullTimeEmployees": 120, "companyOfficers": [{"maxAge": 1, "name": "Dr. Jay R. Luly Ph.D.", "age": 69, "title": "President, CEO & Director", "yearBorn": 1956, "fiscalYear": 2025, "totalPay": 742273, "exercisedValue": 0, "unexercisedValue": 491378}, {"maxAge": 1, "name": "Dr. Yat Sun Or Ph.D.", "age": 73, "title": "Chief Scientific Officer", "yearBorn": 1952, "fiscalYear": 2025, "totalPay": 814285, "exercisedValue": 0, "unexercisedValue": 163342}, {"maxAge": 1, "name": "Dr. Scott T. Rottinghaus M.D.", "age": 51, "title": "Chief Medical Officer", "yearBorn": 1974, "fiscalYear": 2025, "totalPay": 863706, "exercisedValue": 0, "unexercisedValue": 147325}, {"maxAge": 1, "name": "Mr. Harry R. Trout III", "age": 56, "title": "VP of Finance & Interim Principal Financial Officer", "yearBorn": 1969, "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jennifer  Viera", "title": "Executive Director of Investor Relations & Corporate Communications", "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew P. Kowalsky J.D.", "age": 52, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1973, "fiscalYear": 2025, "totalPay": 575652, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Nathaniel S. Gardiner J.D.", "age": 71, "title": "Consultant", "yearBorn": 1954, "fiscalYear": 2025, "totalPay": 672675, "exercisedValue": 49136, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Tara Lynn Kieffer Ph.D.", "age": 47, "title": "Chief Product Strategy Officer", "yearBorn": 1978, "fiscalYear": 2025, "totalPay": 496852, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Brendan  Luu", "age": 50, "title": "Chief Business Officer", "yearBorn": 1975, "fiscalYear": 2025, "totalPay": 622856, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 4, "compensationRisk": 6, "shareHolderRightsRisk": 8, "overallRisk": 6, "governanceEpochDate": 1769904000, "compensationAsOfEpochDate": 1767139200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 14.0, "open": 13.89, "dayLow": 13.025, "dayHigh": 14.16, "regularMarketPreviousClose": 14.0, "regularMarketOpen": 13.89, "regularMarketDayLow": 13.025, "regularMarketDayHigh": 14.16, "payoutRatio": 0.0, "beta": 0.986, "forwardPE": -5.127135, "volume": 430175, "regularMarketVolume": 430175, "averageVolume": 289513, "averageVolume10days": 190580, "averageDailyVolume10Day": 190580, "bid": 13.47, "ask": 13.58, "bidSize": 1, "askSize": 1, "marketCap": 392051360, "fiftyTwoWeekLow": 4.09, "fiftyTwoWeekHigh": 17.15, "allTimeHigh": 127.77, "allTimeLow": 4.09, "priceToSalesTrailing12Months": 5.85326, "fiftyDayAverage": 14.0242, "twoHundredDayAverage": 10.094075, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 399385344, "profitMargins": -1.06804, "floatShares": 20199205, "sharesOutstanding": 29019344, "sharesShort": 2260780, "sharesShortPriorMonth": 2083389, "sharesShortPreviousMonthDate": 1767139200, "dateShortInterest": 1769731200, "sharesPercentSharesOut": 0.0779, "heldPercentInsiders": 0.04694, "heldPercentInstitutions": 0.91436, "shortRatio": 8.62, "shortPercentOfFloat": 0.0933, "impliedSharesOutstanding": 29019344, "bookValue": 4.362, "priceToBook": 3.0972033, "lastFiscalYearEnd": 1759190400, "nextFiscalYearEnd": 1790726400, "mostRecentQuarter": 1767139200, "netIncomeToCommon": -71537000, "trailingEps": -3.21, "forwardEps": -2.635, "enterpriseToRevenue": 5.963, "enterpriseToEbitda": -5.862, "52WeekChange": 0.67865705, "SandP52WeekChange": 0.14684999, "quoteType": "EQUITY", "currentPrice": 13.51, "targetHighPrice": 28.0, "targetLowPrice": 12.0, "targetMeanPrice": 20.25, "targetMedianPrice": 20.0, "recommendationMean": 1.57143, "recommendationKey": "buy", "numberOfAnalystOpinions": 8, "totalCash": 185848992, "totalCashPerShare": 6.404, "ebitda": -68132000, "totalDebt": 193183008, "quickRatio": 4.345, "currentRatio": 4.442, "totalRevenue": 66980000, "debtToEquity": 152.604, "revenuePerShare": 2.885, "returnOnAssets": -0.13467, "returnOnEquity": -0.60012, "grossProfits": 66980000, "freeCashflow": -1043125, "operatingCashflow": -14170000, "revenueGrowth": 0.098, "grossMargins": 1.0, "ebitdaMargins": -1.0172, "operatingMargins": -0.60451, "financialCurrency": "USD", "symbol": "ENTA", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Enanta Pharmaceuticals, Inc.", "longName": "Enanta Pharmaceuticals, Inc.", "corporateActions": [], "postMarketTime": 1771626055, "regularMarketTime": 1771621202, "exchange": "NMS", "messageBoardId": "finmb_345286", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "marketState": "CLOSED", "regularMarketChangePercent": -3.5, "regularMarketPrice": 13.51, "priceEpsCurrentYear": -5.7489367, "fiftyDayAverageChange": -0.5142002, "fiftyDayAverageChangePercent": -0.03666521, "twoHundredDayAverageChange": 3.415925, "twoHundredDayAverageChangePercent": 0.33840892, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.6 - Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1363872600000, "postMarketChangePercent": 0.66617435, "postMarketPrice": 13.6, "postMarketChange": 0.09000015, "regularMarketChange": -0.49, "regularMarketDayRange": "13.025 - 14.16", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 289513, "fiftyTwoWeekLowChange": 9.42, "fiftyTwoWeekLowChangePercent": 2.3031783, "fiftyTwoWeekRange": "4.09 - 17.15", "fiftyTwoWeekHighChange": -3.6399994, "fiftyTwoWeekHighChangePercent": -0.21224487, "fiftyTwoWeekChangePercent": 67.86571, "earningsTimestamp": 1770670800, "earningsTimestampStart": 1778533200, "earningsTimestampEnd": 1778533200, "earningsCallTimestampStart": 1715027400, "earningsCallTimestampEnd": 1715027400, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -3.21, "epsForward": -2.635, "epsCurrentYear": -2.35, "displayName": "Enanta Pharmaceuticals", "trailingPegRatio": null, "__fetch_time": "2026-02-21"}]